Pfizer announced results from its Phase 2 trial of tasocitinib for the treatment of adult patients with moderate-to-severe plaque psoriasis. This double-blind, placebo-controlled, dose-ranging study was conducted in 197 patients, who were randomized to receive 2, 5 or 15mg tasocitinib or placebo twice daily.   This trial met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75% reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate-to-severe plaque psoriasis. At week 12, PASI 75 responses for tasocitinib 2, 5 and 15mg twice daily groups were 25%, 40.8% and 66.7% respectively, versus placebo, 2% (all doses, p<0.001).  As early as week 4, treatment with 5 and 15mg twice daily of tasocitinib significantly improved patient reported health-related quality of life outcomes.

Tasocitinib is an investigational oral Janus Kinase (JAK) inhibitor.  It is believed that the JAK pathways play an important role in the psoriasis disease cascade.

For more information call (800) 438-1985 or visit www.pfizer.com.